LNC Group

Who we are

LNC is a microbiome-centric R&D company in the field of obesity and its adjacent metabolic diseases

What we think

Gut disorders, including microbiome perturbations, are the root causes of obesity.

We are strongly convinced that microbiome-based therapies will revolutionize obesity and metabolic disorders management. They will be the only way to combine safety, efficacy and long-term results.

What we do

Thanks to a deep understanding of metabolic disorders and physiopathology, LNC develops gut modulator products to tackle obesity and cardiometabolic diseases.

STABLOR
Medical Nutrition Product
TEMYS PROJECT
Gut ecosystem modulation
How we work

We drive all our development projects from fundamental R&D until clinical demonstration. Our worldwide collaborations with renowned medical experts enable us to maintain the highest level of standards to develop the next generation approach to obesity.

Founders & Direction

From the creation of LNC, the founders shared the same vision: to address the issue of obesity by acting on its root causes

Claude VINCENT
President
+
Claude VINCENT
President

Following his initial studies in economic, sociology and commerce (ESSEC), Claude starting working in the pharmaceutical industry with ROUSSEL UCLAF (subsequently HOESCHT ROUSSEL) where he stayed for 22 years (based in Argentina and Italy), in particular as International Sales and Marketing Director, CEO Italy and President Roussel France. He then returned to France as Associated Shareholder several SME : Leurquin, Proteika Nutrition and Dietic & Co.

Claude became specialised in clinical pharmacology and the study of metabolic syndrome. He took an active part in the creation of LNC.

Claude is also President of French Association for the Prevention of Cardiometabolic Risk, which organises symposia with the National Academy of Medicine on this subject.

Jean-Luc TREILLOU
CEO
+
Jean-Luc TREILLOU
CEO

With a Doctorate of Pharmacy and a qualification from a business school, Jean-Luc started his career in 1995 with SmithKline-Beecham (subsequently GSK) before joining Aventis Pharma (subsequently Sanofi) to work in a variety of industrial and financial roles based in Europe, Asia and Africa (Vietnam, Senegal, Maroc).

Fascinated by the field of nutrition, and convinced of its added value in the global management of patients, for the past ten years Jean-Luc has been focusing on the convergence between nutrition and pharmaceuticals in the context of the changing business model for the life sciences, and has been the manager or director of several SME.

He has also acted as a consultant for European investment funds, pharmaceutical companies and firms specialised in medical nutrition.

Fabrice GUEZ
CFO
+
Fabrice GUEZ
CFO

Graduated from ISG Paris, Fabrice has a double competence financial management and supply chain management gained during a professional experience of 20 years, including as Senior Auditor at KPMG, then as Director, Industrial and Supply Chain in Oenobiol / Sanofi.

Convinced by the innovative approach of LNC project and determined to meet an entrepreneurial challenge, Fabrice joined LNC from its inception.

Jean-Pierre LEHNER
head of laboratory R&D LNC
+
Jean-Pierre LEHNER
head of laboratory R&D LNC

Jean-Pierre LEHNER MD, cardiologist and internal medicine graduate served during 30 years the pharmaceutical industry. Before joining pharmaceutical industry Jean-Pierre was practitioner in Hospital Bichat, Paris (France), where during the last 4 years he was heading the Intensive Care Unit of Cardiology.

Dr. Lehner assumed various roles in medical affairs. In 1981, he joined Roussel-Uclaf Company first as medical director in France, then in charge of international clinical development untill 1992.

Dr. Lehner served successively at sanofi as Head of Clinical Development during 4 years before taking the scientific director position in France until 2002 and developed the European medical team before taking the position of Global Medical Director 2005.

Patrick BIECHELER
partner / Roland Berger / strategy consultants
+
Patrick BIECHELER
partner / Roland Berger / strategy consultants

Since graduating from ESSEC, Patrick Biecheler has spent most of his career as a management consultant, where he has gained nearly 16 years of experience.

Most of Patrick’s missions have been carried out in the health field and pharmaceutical industry, acting for both public sector organisations [notably the MeaH (French National Hospital Audit Commission), ANAP (National Performance Support Mission), DGOS (Directorate General for Healthcare) and DGME (Directorate General for Modernisation of the State)] and private enterprises (pharmaceutical companies and clinics).

He has implemented numerous projects on strategic planning, support for the launch of new products, acceleration of time-to-market, improvement in operational and financial performance and support with restructuring/mergers and acquisitions. Patrick Biecheler also spent some time as Marketing Director for Respiratory-Central Nervous System Products at the drug company AstraZeneca. Patrick Biecheler participated in the development of the Healthcare Industry Cluster at the Paris office, which he currently manages.

Virginie LLEU
Managing Director of L3S Partnership
+
Virginie LLEU
Managing Director of L3S Partnership

Holding a Supplementary Specialised Studies Diploma (DESS) in Clinical Psychopathology, and bilingual in English, she started her professional career by gaining clinical experience in hospitals as a neuropsychologist.

In 1992, Virginie Lleu joined the pharmaceutical company Jouveinal to work in its Human Resources Directorate. She then moved as a consultant to a recruitment agency specialised in the healthcare field, GSA, subsequently joining Pact & Partners International as Senior Consultant responsible for the Health and Biotechnologies sector.

As from 2000, Virginie pursued her work as a recruitment consultant with Executive Search International entities such as Korn Ferry International and Spencer Stuart, where she contributed to developing the Health and Biotechnologies Department.

After accomplishing a large number of missions in a variety of functions (general management, R&D, marketing/sales, manufacturing, business development, HR, finance, etc.), in 2003 Virginie founded L2S (Life Science Search), a recruitment consultancy based on direct contact and dedicated specifically to healthcare. L2S soon became a market leader in the life sciences in France and Europe. Five years after it was set up, in 2008, L2S was sold to Whitehead Mann, and Virginie Lleu became Senior Client Partner Life Sciences for Europe, supervising a team of some fifteen people.Drawing on her wide-ranging and significant experience and expertise developed at L2S, in October 2010 Virginie Lleu created the L3S Partnership, the aim being to become one of the leading executive search companies for the life sciences in Europe.

Jean-Michel PETIT
Director of Participations, IRDI
+
Jean-Michel PETIT
Director of Participations, IRDI

Jean-Michel Petit heads the venture capital and seed funding activities of the IRDI Group. He is thus Director General of IRDInov, the regional seed-stage fund for south-western France. Before joining IRDI, he spent 10 years in Canada, notably working in the venture capital branch of the Caisse de Dépôt du Québec where he participated actively in investing in companies and venture capital funds in both Canada and the USA and Europe.
IRDI is based in Toulouse, and has been present throughout the Aquitaine and Midi-Pyrénées for more than thirty years. Its investments target industrial companies and/or innovative enterprises at different stages of their development. The IRDI team manages funds worth more than €125 billion via the IRDI, MPC, IRDInov, FAM and SOCRI vehicles.

Jean-Michel PETIT qualified as an Engineer from the National Chemical Engineering School in Paris, and gained an MSc from the Université de Montréal and an MBA from McGill University.
Isabelle de CREMOUX
President & CEO, Seventure Partners
+
Isabelle de CREMOUX
President & CEO, Seventure Partners

Isabelle brings 25 years of international experience in life sciences business development and finance. She started her career in ’91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development.

Since ’98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the lifesciences department.

Isabelle leads the lifesciences team and makes direct investments, mainly  in France and Scandinvia  with a focus on biotech, nutrition, personalized medicine and especially microbiome. Isabelle’s trackrecord includes Santaris (solde to Roche for $450 millions in august 2014), argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

Frédérique WELGRYN
Head of operations, HRA pharma
+
Frédérique WELGRYN
Head of operations, HRA pharma

After becoming a Doctor of Pharmacy and obtaining a postgraduate qualification in marketing and management, Frédérique WELGRYN gained 15 years of experience in the pharmaceutical industry.

She worked as a marketing, sales or Business Unit manager for major pharmaceutical groups such as Roche, AstraZeneca and Sanofi, after which she became a management consultant in the Strategy Division of Cap Gemini Ernst &Young.

She is currently international Head of Operations for Women’s Health at HRA Pharma.

Shareholers

LNC is backed by renowned investors, one of which is Seventure Partners, a key player in European venture capital in the field of Life Sciences

Publications

In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials

Discover our selection

Find out more
The strong protective role of...
Variation in the human fecal microbiota has previously been associated with body mass index (BMI)....
C.minuta is the species related...
Host genetics and the gut microbiome can both influence metabolic phenotypes. Here, Goodrich et al....
What is the link between...
Evidence suggests the gut microbiome is involved in the development of cardiovascular disease (CVD),...